171 related articles for article (PubMed ID: 22397670)
1. Germline JAK2 mutation in a family with hereditary thrombocytosis.
Mead AJ; Rugless MJ; Jacobsen SE; Schuh A
N Engl J Med; 2012 Mar; 366(10):967-9. PubMed ID: 22397670
[No Abstract] [Full Text] [Related]
2. Germline
Aral B; Courtois M; Ragot S; Bourgeois V; Bottolier-Lemallaz E; Briandet C; Girodon F
Haematologica; 2018 Aug; 103(8):e372-e373. PubMed ID: 29567786
[No Abstract] [Full Text] [Related]
3. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.
Marty C; Saint-Martin C; Pecquet C; Grosjean S; Saliba J; Mouton C; Leroy E; Harutyunyan AS; Abgrall JF; Favier R; Toussaint A; Solary E; Kralovics R; Constantinescu SN; Najman A; Vainchenker W; Plo I; Bellanné-Chantelot C
Blood; 2014 Feb; 123(9):1372-83. PubMed ID: 24398328
[TBL] [Abstract][Full Text] [Related]
4. Progression to polythythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation.
Maie K; Yokoyama Y; Yano Y; Kato T; Nannya Y; Ogawa S; Noguchi M; Sakata-Yanagimoto M; Chiba S
Ann Hematol; 2018 Apr; 97(4):737-739. PubMed ID: 29368262
[No Abstract] [Full Text] [Related]
5. Hereditary erythrocytosis, thrombocytosis and neutrophilia.
Hong WJ; Gotlib J
Best Pract Res Clin Haematol; 2014 Jun; 27(2):95-106. PubMed ID: 25189721
[TBL] [Abstract][Full Text] [Related]
6. A novel JAK2 R564* variant in a patient with thrombocytosis.
Villanueva A; Poon KS; Gallardo CA; Chai CN; Chiu L; Yan B; Ding CSL; Yong KJ; Zhou J; Lee J; Tan K; Ong KH
Int J Lab Hematol; 2020 Apr; 42(2):e38-e41. PubMed ID: 31441587
[No Abstract] [Full Text] [Related]
7. Essential thrombocytosis attributed to JAK2-T875N germline mutation.
Yoshimitsu M; Hachiman M; Uchida Y; Arima N; Arai A; Kamada Y; Shide K; Ito M; Shimoda K; Ishitsuka K
Int J Hematol; 2019 Nov; 110(5):584-590. PubMed ID: 31428969
[TBL] [Abstract][Full Text] [Related]
8. A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline.
Carreño-Tarragona G; Varghese LN; Sebastián E; Gálvez E; Marín-Sánchez A; López-Muñoz N; Nam-Cha S; Martínez-López J; Constantinescu SN; Sevilla J; Ayala R
Leukemia; 2021 Nov; 35(11):3295-3298. PubMed ID: 33846542
[No Abstract] [Full Text] [Related]
9. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Renneville A; Quesnel B; Charpentier A; Terriou L; Crinquette A; Laï JL; Cossement C; Lionne-Huyghe P; Rose C; Bauters F; Preudhomme C
Leukemia; 2006 Nov; 20(11):2067-70. PubMed ID: 16990759
[No Abstract] [Full Text] [Related]
10. Diagnostic workflow for hereditary erythrocytosis and thrombocytosis.
McMullin MF
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):391-396. PubMed ID: 31808840
[TBL] [Abstract][Full Text] [Related]
11. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.
Gattermann N; Billiet J; Kronenwett R; Zipperer E; Germing U; Nollet F; Criel A; Selleslag D
Blood; 2007 Feb; 109(3):1334-5. PubMed ID: 17244688
[No Abstract] [Full Text] [Related]
12. Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation.
Lu CM; Zhou L; Wang E; Feng S; Sebastian S; Behler C
Leuk Lymphoma; 2011 Dec; 52(12):2405-7. PubMed ID: 21806348
[No Abstract] [Full Text] [Related]
13. Hereditary thrombocytosis: the genetic landscape.
Han EY; Catherwood M; McMullin MF
Br J Haematol; 2021 Sep; 194(6):1098-1105. PubMed ID: 34341988
[No Abstract] [Full Text] [Related]
14. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of JAK2 V617F to CALR-mutated clones accelerates disease progression and might enhance growth capacity.
Nishimura M; Nagaharu K; Ikejiri M; Sugimoto Y; Sasao R; Ohya E; Mizutani M; Ohishi K; Tawara I; Sekine T
Br J Haematol; 2021 Sep; 194(5):e89-e92. PubMed ID: 34060068
[No Abstract] [Full Text] [Related]
16. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.
Flach J; Dicker F; Schnittger S; Kohlmann A; Haferlach T; Haferlach C
Haematologica; 2010 Mar; 95(3):518-9. PubMed ID: 19903679
[No Abstract] [Full Text] [Related]
17. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis.
Pemmaraju N; Moliterno AR; Williams DM; Rogers O; Spivak JL
Leukemia; 2007 Oct; 21(10):2210-2. PubMed ID: 17507997
[No Abstract] [Full Text] [Related]
18. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.
Jeromin S; Haferlach T; Grossmann V; Alpermann T; Kowarsch A; Haferlach C; Kern W; Schnittger S
Haematologica; 2013 Feb; 98(2):e15-7. PubMed ID: 22929973
[No Abstract] [Full Text] [Related]
19. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis with co-mutated JAK2 and SF3B1.
Reinig EF; He R
Blood; 2017 Feb; 129(5):656. PubMed ID: 28153838
[No Abstract] [Full Text] [Related]
[Next] [New Search]
